علاج داء البابيزيا في المرضى المتلقين للريتوكسيماب لسرطان الغدد الليمفاوية للخلايا البائية أو في حالة نقص مناعة شديد

References

DOI: 10.1093/cid/ciab275

• They include those who (i) have received or are receiving rituximab for B cell lymphoma or an autoimmune disorder, (ii) are receiving other immunosuppressive regimens for solid organ or bone marrow transplantation or malignancy, (iii) have malignancy and are asplenic, or (iv) have HIV infection with low CD4 T cell counts (AIDS).
• Start with one of the regimens recommended for hospitalized patients: acute severe disease and follow with one of the step-down therapies but treat for at least 6 consecutive weeks, including 2 final weeks during which parasites are no longer detected on peripheral blood smear [3].
• A retrospective case-control study of 14 such patients who were infected with B. microti has shown that complete cure typically requires ≥6 consecutive weeks of antimicrobial treatment, including 2 final weeks during which parasites are no longer detected on peripheral blood smear [29].